January 2025 FDA Recall Irbesartan by Avkare
D-0224-2025 - Out of Specification for Dissolution
This Class II drug recall was voluntarily initiated by Avkare on January 21, 2025 for the product Irbesartan. The FDA reported the reason for recall as out of specification for dissolution. The product was distributed Nationwide and the recall is currently ongoing.
Recall Number: D-0224-2025
Out of Specification for Dissolution
01-21-2025
02-19-2025
341 cartons
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Ongoing
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
AvKARE
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Nationwide in the USA
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Irbesartan Tablets USP, 300 mg, 50 Tablets (5 x 10) Unit Dose per carton, Manufactured for: AvKARE, Pulaski, TN 38478. NDC 50268-442-15
Batch or Lot Expiration Information
Lot# Lot 45279, Exp 03/31/2025
